Drugmaker Amgen Inc will pay about $1.9 billion in cash for Five Prime Therapeutics, adding a late-stage gastric cancer drug candidate to its line of cancer drugs, the companies said on Thursday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,